Scarica l'app Stockscreener
3.39
0.59%
-0.02
Pre-mercato:
3.39
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RVNC Giù?
Forum
Previsione
Precedente Chiudi:
$3.41
Aprire:
$3.45
Volume 24 ore:
2.37M
Relative Volume:
0.90
Capitalizzazione di mercato:
$353.88M
Reddito:
$234.04M
Utile/perdita netta:
$-323.92M
Rapporto P/E:
-0.8921
EPS:
-3.8
Flusso di cassa netto:
$-223.46M
1 W Prestazione:
+10.78%
1M Prestazione:
+11.88%
6M Prestazione:
+17.30%
1 anno Prestazione:
-51.78%
Intervallo 1D:
$3.3505
$3.495
Intervallo di 1 settimana:
$3.05
$3.61
Portata 52W:
$2.30
$7.56
Revance Therapeutics Inc Stock (RVNC) Company Profile
Nome
Revance Therapeutics Inc
Settore
Industria
Telefono
(615) 724-7755
Indirizzo
1222 DEMONBREUN STREET, NASHVILLE, CA
Confronta RVNC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RVNC
Revance Therapeutics Inc
|
3.39 | 353.88M | 234.04M | -323.92M | -223.46M | -3.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.11 | 106.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.59 | 80.61B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
649.26 | 38.82B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.55 | 31.03B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.15 | 29.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Revance Therapeutics Inc Stock (RVNC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-01-29 | Downgrade | Mizuho | Buy → Neutral |
| 2024-01-09 | Downgrade | Goldman | Buy → Neutral |
| 2023-08-16 | Aggiornamento | Exane BNP Paribas | Underperform → Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-09-22 | Iniziato | Goldman | Buy |
| 2021-10-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-10-15 | Reiterato | Needham | Buy |
| 2020-08-11 | Ripresa | Mizuho | Buy |
| 2020-03-23 | Downgrade | Goldman | Buy → Neutral |
| 2019-12-02 | Iniziato | Goldman | Buy |
| 2019-10-30 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-02-15 | Iniziato | Wells Fargo | Market Perform |
| 2019-02-14 | Iniziato | H.C. Wainwright | Buy |
| 2019-01-29 | Iniziato | Stifel | Buy |
| 2018-11-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2018-09-17 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-04-20 | Reiterato | Mizuho | Buy |
| 2018-03-27 | Iniziato | Needham | Buy |
| 2018-03-05 | Iniziato | Goldman | Buy |
| 2018-01-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2017-12-06 | Iniziato | Guggenheim | Buy |
| 2017-12-06 | Reiterato | Mizuho | Buy |
| 2017-11-27 | Iniziato | Barclays | Overweight |
| 2017-11-17 | Iniziato | Mizuho | Buy |
| 2017-08-22 | Iniziato | JMP Securities | Mkt Outperform |
Mostra tutto
Revance Therapeutics Inc Borsa (RVNC) Ultime notizie
RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Morningstar
RVNC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance LawsuitRVNC - Marketscreener.com
Class Action Filed Against Revance Therapeutics, Inc. - GlobeNewswire
Revance Therapeutics jumps after Teoxane offers $3.60 a share - MSN
Revance gains as it plans to enter talks with Teoxane on likely superior bid - MSN
Revance to Hold Talks With Teoxane on Takeover Proposal - MarketWatch
Revance gains as it plans to enter talks with Teoxane on likely superior bid (RVNC:NASDAQ) - Seeking Alpha
REVANCE ALERT: Bragar Eagel & Squire, P.C. Announces that a - GlobeNewswire
RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Benzinga
Stockholder Notice: Robbins LLP Informs Stockholders of the Revance Therapeutics, Inc. Class Action Lawsuit - PR Newswire
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Law Offices of Frank R. Cruz Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class Action - Business Wire
Biotech Co. Revance Faces Suit After Tender Offer Weakens - Law360
RVNC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Teoxane Outbids Crown With New Revance Therapeutics Bid - Law360
Law Offices of Howard G. Smith Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class Action - Marketscreener.com
Revance Therapeutics Stock’s Retail Sentiment Muted Even As Teoxane Makes Better Offer Than Crown Labs - MSN
SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Teoxane makes cash offer to buy Revance Therapeutics By Investing.com - Investing.com Canada
Revance Therapeutics Shares Rise as Teoxane Looks to Upend Crown Deal - MarketWatch
Revance Therapeutics jumps after Teoxane offers $3.60 a share (NASDAQ:RVNC) - Seeking Alpha
Teoxane makes cash offer to buy Revance Therapeutics - Investing.com
Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in Cash - Yahoo Finance
Teoxane S.A. submitted a proposal to acquire all remaining stake in Revance Therapeutics, Inc. for $360 million. - Marketscreener.com
StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Revance Therapeutics (RVNC) Investors with Losses to Contact Firm’s Attorneys Before Feb. 8th Deadline in Securities Fraud Action - AccessWire
Revance Therapeutics, Inc. (NASDAQ:RVNC) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
HAGENS BERMAN, NATIONAL TRIAL ATTOREYS, Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firm’s Attorneys Now, Firm Investigating Possible Securities Law Violations - AccessWire
Revance Therapeutics, Inc. (NASDAQ:RVNC) Short Interest Down 23.1% in December - MarketBeat
StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
Revance Therapeutics (NASDAQ:RVNC) Given New $3.00 Price Target at Barclays - MarketBeat
Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by Franklin Resources Inc. - MarketBeat
Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com - MarketBeat
Revance Therapeutics ticks higher as holder says Crown deal undervalues company - MSN
HighTower Advisors LLC Lowers Stock Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
Wellington Management Group LLP Invests $2.32 Million in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc.RVNC - Business Wire
Revance Therapeutics' SWOT analysis: tender offer shakes up specialty pharma stock - Investing.com
725,000 Shares in Revance Therapeutics, Inc. (NASDAQ:RVNC) Acquired by Oddo BHF Asset Management Sas - MarketBeat
Revance receives acquisition offer from Crown Laboratories for $3.10 per share - Yahoo Finance
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc.RVNC - Kilgore News Herald
Shareholder Alert: Ademi LLP Investigates Whether Revance Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Marketscreener.com
Crown Laboratories Commences Friendly Tender Offer for All Outst - GuruFocus.com
Crown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3.10 per share - Marketscreener.com
Kirkland Advises Crown Laboratories on Amended Merger Agreement with Revance - Legal Desire News Network
Crown Labs announces merger with Revance Therapeutics - Johnson City Press
Revance Therapeutics' SWOT analysis: crown's tender offer lifts stock outlook By Investing.com - Investing.com Nigeria
Revance Therapeutics' SWOT analysis: crown's tender offer lifts stock outlook - Investing.com India
Crown Labs and Revance Therapeutics closer to merging - SuperTalk 92.9
Revance Therapeutics Inc Azioni (RVNC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.08%
0.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):